Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DARE Dare Bioscience	$2.12 +1.0%	$2.45	$1.83 ▼ $9.19	$28.58M	1.11	253,897 shs	155,086 shs
LIXT Lixte Biotechnology	$3.41 +3.0%	$3.12	$0.64 ▼ $5.14	$15.55M	0.43	141,112 shs	131,021 shs
MBRX Moleculin Biotech	$0.57 -4.9%	$0.57	$0.25 ▼ $3.65	$17.19M	1.39	2.52 million shs	1.94 million shs
PALI Palisade Bio	$0.75 +3.9%	$0.82	$0.60 ▼ $4.32	$6.88M	1.35	5.44 million shs	207,588 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DARE Dare Bioscience	0.00%	-3.64%	-17.51%	-26.90%	-40.28%
LIXT Lixte Biotechnology	0.00%	-5.01%	-17.03%	+158.33%	+89.44%
MBRX Moleculin Biotech	0.00%	-16.84%	+0.11%	-40.32%	-76.25%
PALI Palisade Bio	0.00%	-5.87%	-35.00%	-6.57%	-78.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DARE Dare Bioscience	2.5383 of 5 stars	3.5	5.0	2.6	0.0	0.0
LIXT Lixte Biotechnology	0.0482 of 5 stars	0.0	2.0	0.0	0.8	0.0
MBRX Moleculin Biotech	3.0558 of 5 stars	3.5	4.0	1.3	1.7	1.3
PALI Palisade Bio	2.7915 of 5 stars	3.5	4.0	1.9	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DARE Dare Bioscience	3.00	Buy	$12.00	466.04% Upside
LIXT Lixte Biotechnology	0.00	N/A	N/A	N/A
MBRX Moleculin Biotech	3.00	Buy	$4.00	604.72% Upside
PALI Palisade Bio	3.00	Buy	$12.00	1,491.51% Upside

Current Analyst Ratings Breakdown

Latest PALI, DARE, MBRX, and LIXT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/18/2025	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/9/2025	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$4.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DARE Dare Bioscience	-$17.70K	-1,614.46	N/A	N/A	($0.69) per share	-3.07
LIXT Lixte Biotechnology	N/A	N/A	N/A	N/A	($1.19) per share	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	$1.77 per share	N/A
PALI Palisade Bio	$250K	27.51	N/A	N/A	$2.71 per share	0.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DARE Dare Bioscience	-$4.05M	-$2.14	N/A	N/A	N/A	N/A	N/A	-103.70%	11/13/2025 (Estimated)
LIXT Lixte Biotechnology	-$3.59M	-$1.29	N/A	∞	N/A	N/A	N/A	-222.90%	11/10/2025 (Estimated)
MBRX Moleculin Biotech	-$21.76M	N/A	0.00	N/A	N/A	N/A	-1,498.41%	-114.47%	N/A
PALI Palisade Bio	-$14.44M	-$4.06	N/A	N/A	N/A	N/A	-214.94%	-135.09%	11/11/2025 (Estimated)

Latest PALI, DARE, MBRX, and LIXT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	DARE Dare Bioscience	-$0.55	-$0.45	+$0.10	-$0.45	$0.14 million	($0.02) million
8/12/2025	Q2 2025	MBRX Moleculin Biotech	-$0.39	-$0.49	-$0.10	-$0.49	N/A	N/A
8/11/2025	Q2 2025	PALI Palisade Bio	-$0.48	-$0.58	-$0.10	-$0.58	N/A	N/A
8/7/2025	Q2 2025	LIXT Lixte Biotechnology	N/A	-$0.29	N/A	-$0.29	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DARE Dare Bioscience	N/A	N/A	N/A	N/A	N/A
LIXT Lixte Biotechnology	N/A	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	N/A
PALI Palisade Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DARE Dare Bioscience	N/A	0.34	0.34
LIXT Lixte Biotechnology	N/A	1.84	1.84
MBRX Moleculin Biotech	N/A	1.15	1.15
PALI Palisade Bio	N/A	1.62	1.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DARE Dare Bioscience	6.70%
LIXT Lixte Biotechnology	5.10%
MBRX Moleculin Biotech	15.52%
PALI Palisade Bio	11.79%

Insider Ownership

Company	Insider Ownership
DARE Dare Bioscience	4.80%
LIXT Lixte Biotechnology	14.80%
MBRX Moleculin Biotech	2.10%
PALI Palisade Bio	0.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DARE Dare Bioscience	30	13.48 million	12.83 million	Not Optionable
LIXT Lixte Biotechnology	4	4.56 million	3.89 million	Not Optionable
MBRX Moleculin Biotech	20	30.29 million	29.65 million	Not Optionable
PALI Palisade Bio	10	9.12 million	9.06 million	Not Optionable

PALI, DARE, MBRX, and LIXT Headlines

Recent News About These Companies

Q3 EPS Estimates for Palisade Bio Reduced by Analyst

August 17, 2025 | americanbankingnews.com

Palisade Bio files to sell 8.9M shares of common stock for holders

August 16, 2025 | msn.com

Palisade reports outcomes from Phase Ib ulcerative colitis study

August 11, 2025 | finance.yahoo.com

Palisade Bio’s PALI-2108: A Promising New Treatment for Ulcerative Colitis

August 8, 2025 | msn.com

Palisade Bio Reports Positive Phase 1b Data for PALI-2108 in Ulcerative Colitis Demonstrating Safety and Efficacy

August 7, 2025 | quiverquant.comQ

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

August 7, 2025 | globenewswire.com

Palisade Bio’s locally-activated, terminal ileum and colon-targeted PDE4 B/D inhibitor, PALI-2108 receives Chinese patent

August 4, 2025 | pharmabiz.comP

Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China

July 31, 2025 | globenewswire.com

Palisade Bio’s Phase 1 Study on PALI-2108: A New Hope for Ulcerative Colitis Treatment

July 30, 2025 | tipranks.com

Palisade Bio, Inc. Announces Agreement to Exercise Existing Warrants and Raise Approximately $3.9 Million

July 23, 2025 | quiverquant.comQ

Palisade Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

July 23, 2025 | finance.yahoo.com

Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million

July 23, 2025 | finance.yahoo.com

Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million

July 23, 2025 | globenewswire.com

Palisade Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

July 22, 2025 | globenewswire.com

Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of ...

July 11, 2025 | morningstar.comM

Palisade Bio, Inc. Appoints Dr. Emil Chuang to Board of ... - Nasdaq

July 11, 2025 | nasdaq.com

Palisade Bio appoints to its Board of Directors

July 9, 2025 | msn.com

Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors

July 9, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/07/09/3112579/0/en/palisade-bio-appoints-emil-chuang-mb-bs-fracp-to-its-board-of-directors.html$

Transpire follows in Boehringer's footsteps by licensing PDE4 inhibitor for lung disease

June 3, 2025 | fiercebiotech.comF

Palisade Bio Reports Improved Quarterly Losses

June 2, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PALI, DARE, MBRX, and LIXT Company Descriptions

Dare Bioscience NASDAQ:DARE

$2.12 +0.02 (+0.95%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.25 +0.13 (+6.32%)

As of 07:07 AM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Lixte Biotechnology NASDAQ:LIXT

$3.41 +0.10 (+3.02%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.31 -0.10 (-2.93%)

As of 06:00 AM Eastern

LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

Moleculin Biotech NASDAQ:MBRX

$0.57 -0.03 (-4.88%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.57 +0.01 (+0.95%)

As of 07:18 AM Eastern

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Palisade Bio NASDAQ:PALI

$0.75 +0.03 (+3.86%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.75 0.00 (-0.13%)

As of 07:22 AM Eastern

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time